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ABSTRACT 
 
 This thesis examines the connection between epithelial to mesenchymal 
transition (EMT) and cancer stem cells (CSC) in solid tumors. Epithelial to 
mesenchymal transition describes the conversion of cancer cells from an adherent, 
differentiated, and polar phenotype (epithelial) to a motile, plastic, and apolar 
phenotype (mesenchymal). EMT is correlated with metastasis; EMT is usually 
measured by QRT-PCR or immunohistochemistry. Cancer stem cells are thought to 
be responsible for metastasis and recurrence. They have been found in almost all 
solid tumors and cancer stem cell-enriched populations are detectable using flow 
cytometry. 
 EMT and cancer stem cells have many jeans, transcription factors, and 
signaling pathways in common. Both have been clinically correlated with patient 
outcomes and disease-free survival. There’s currently no consensus on mechanistic 
connection between the two phenomena. The current data on critical signaling 
pathways as well as the effect of the tumor stroma and cytotoxic therapy is 
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examined. The current body of research points to the conclusion that EMT may be 
responsible for the cancer stem cell-enriched populations in solid tumors. 
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BODY OF TEXT  
Introduction 
 The goal of this thesis is to elucidate the connection between cancer 
stem cells and epithelial to mesenchymal transition. Epithelial to 
mesenchymal transition (EMT) and cancer stem cells (CSCs) are strongly 
linked to the probability of metastasis and recurrence (Biddle & Mackenzie, 
2012; Grotenhuis, Wijnhoven, & van Lanschot, 2012; Morel et al., 2008; 
Singh & Settleman, 2010). Understanding each phenomenon, as well as their 
connection, will help us develop better diagnostic tools and treatments - 
which will increase disease-free survival. 
Cancer is a collection of diverse diseases. It originates from the 
patient’s own cells, which have begun to replicate uncontrollably. Cancer is 
classified by its organ and cell of origin (Denis, 1992). Cancer can be benign 
or malignant. Benign tumors are usually surgically resected and have a much 
lower mortality rate than their malignant counterparts since they do not 
metastasize. While there are common trends in tumorigenesis, cancers 
originating from different organs will behave in different manners and require 
different treatment. This thesis will focus on solid tumors. This excludes 
lymphomas, leukemias, and myelomas. 
The initial step tumorigenesis involves a mutation in the DNA of a cell. 
It can be anything from a point mutation, to a translocation of a piece of the 
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chromosome, to a deletion of part of or an entire chromosome. Mutations 
occur relatively often, but normally a damaged cell will undergo apoptosis 
(controlled cell death) or the DNA will be repaired. Thus, the mutation has to 
inactivate or inappropriately activate part of the apoptosis machinery, which 
lets the cell bypass the normal pathway of senescence, damage, and death. 
This characteristic, evading apoptosis, is considered one of the hallmarks of 
cancer (Figure 1) (Hanahan & Weinberg, 2000). Another hallmark is 
replicative ability – a cancer cell is able to divide endlessly. 
 The initial mutation will allow the cell to reenter the cycle of growth and 
cell division. As the cell continues to grow, it will have to produce its own 
growth signals. It will also have to resist anti-growth signals from surrounding 
tissue. At this stage, the tumor is usually referred to as a carcinoma in situ. 
This means (for solid tumors of epithelial origin) that the tumor has not 
spread deeper than or crossed the basement membrane. 
 As the tumor grows larger, cells will mutate and dedifferentiate. This 
means they will revert back to a stem cell phenotype. Different tumors form 
different patients will regress at different rates. In fact, within one tumor, there 
will be a range of phenotypes. This is known as tumor heterogeneity. As the 
size of the tumor increases, nutrients will no longer be able to diffuse across 
the extracellular space and the cancer cells will release angiogenic factors.  
 3 
Angiogenesis is the formation of new blood vessels; these vessels will 
supply the tumor with oxygen and metabolites. The low concentration of 
oxygen (hypoxia) drives angiogenesis by upregulating transcription factors 
like vascular endothelial growth factor (VEGF) which promote the formation 
of new blood vessels. The final step in cancer progression is metastasis. The 
cancer cell invades a blood or lymph vessel (called intravasation) and uses it 
to travel to other locations in the body. Eventually, the cell(s) exit the blood or 
lymph vessel (called extravasation) to generate a new tumor in a new site. 
When cancer reaches this stage, it is often fatal (Lodish et al., 1999). 
There are hereditary mutations that increase a person’s chances of 
being diagnosed with a particular type of cancer (i.e. BRCA1 and BRCA2 for 
breast cancer (Weitzel JN, 2007)). However, these only account for 10% of 
all cancers (Agnarsson et al., 1998). 
Most solid tumors are classified by organ of origin and graded using 
the TNM system (Denis, 1992): T stands for tumor size; N stands for the 
number and location of lymph nodes; M indicates the presence of a 
metastatic lesion.  Table 1 shows the criteria used for lung cancer, as an 
example. T1 through T4 represent the size of the tumor. N0 through N3 
represent the local spread of the cancer to lymph nodes. M is a binary 
indicator for whether metastasis is present or not. The TNM stage indicates 
to the medical team how advanced the cancer is. The pathologist may also 
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remark on how differentiated the cancer cells are. A poorly differentiated 
cancer is more likely to be aggressive and recurrent. 
 Thus, the patient with a T1N0M0 tumor may only need surgical 
resection. A T3N3M0 patient may receive cytotoxic drugs or radiation (or 
both) in addition to surgery. If the tumor is positive for a mutation for which 
there is a specific inhibitor, that drug may be added to the treatment regimen. 
This is, unfortunately, the current extent of ‘customization’ of cancer 
treatment. 
Diagnostic tests, rather than treating the tumor, would help determine 
which treatments are best. Tests might include evaluating tumors for 
common mutations or subtypes (i.e. lung cancer with high levels of epidermal 
growth factor receptor). The value of a diagnostic test depends on its 
accuracy and reliability. Thus, it is essential to understand what expression 
patterns indicate the likelihood of metastasis. Another important 
characteristic to determine is the possibility of recurrence. Metastasis and 
recurrence are the most important factors because they are indicators of 
disease-free survival – either is usually fatal. 
 Recurrence is important because even if a solid tumor is completely 
resected, cancerous cells may be left behind. To that end, cancer survivors 
get follow-up scans to make sure their tumor has not come back – either in 
the organ of origin or as a metastasis. Sampling local lymph nodes helps 
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lower the chances of recurrence by identifying when tumors have already 
spread locally. However, there are limits to detection. Thus, a diagnostic test 
that provides a probability of metastasis or recurrence would inform 
physicians how extensive testing needs to be. 
 Determining what genes are involved in cancer progression and 
metastasis is a lengthy endeavor. While oncogenic genes are often involved 
in cell cycle regulation (Cooper, 2000), metastatic genes are usually involved 
with cell motility, adherence, and plasticity (J. Yang & Weinberg, 2008). 
There is a crosstalk between the pathways but it is not unusual for individual 
genes to be implicated in more than one process. 
 One method of determining important genes in cancer development 
and progression is brute force analysis. By sampling tumors of several 
stages, which genes are upregulated as the tumor progresses can be 
identified. However, given the heterogeneity of tumors themselves as well as 
individual variation between patients, this method requires an extremely large 
sample size since the variation between and within samples is significant.  
Many genes involved in tumor progression are related to cell adherence, 
motility, and plasticity (J. Yang & Weinberg, 2008). The significance of 
adherence and motility are clear; to metastasize, the cell must ‘detach’ from 
the local environment, enter into a blood or lymph vessel, exit the vessel, 
travel to a new location, and then establish itself in a new environment 
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(Chiang & Massagué, 2008). Plasticity is important so that once the 
metastatic cell reaches the new organ it can change its characteristics and 
revert to the adherent, non-motile phenotype, as well as make changes to 
adapt to its new environment. 
 Changing from adherent, polar, and differentiated to motile, apolar, 
and plastic is called epithelial to mesenchymal transition (EMT) and it 
appears to be essential to tumor progression (Savagner, Yamada, & Thiery, 
1997). The process is distinct from initial tumorigenesis, although there are 
molecular signaling pathways common to both. Like tumorigenesis, the path 
to metastasis is not linear. Within a tumor, phenotypes will be 
heterogeneous. Some cells will be more mesenchymal than others – but it is 
not necessary for all the cells in a given tumor to be metastatic. 
 Thus, a diagnostic test directed at EMT will provide information about 
the likelihood of the tumor metastasizing. More aggressive tumors will then 
receive correspondingly aggressive treatment. Physicians may be able to 
provide more accurate prognoses. Unfortunately, correlation of EMT with 
recurrence and disease-free survival is not firmly established, since different 
studies have reached different conclusions (Biddle & Mackenzie, 2012; 
DiMeo et al., 2009; Kasimir-Bauer, Hoffmann, Wallwiener, Kimmig, & Fehm, 
2012; Singh & Settleman, 2010). Dimeo et al. found “a molecular link 
between self-renewal, EMT, and metastasis in basal-like breast cancers”; 
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Singh et al. also claimed “the emergence of CSCs occurs in part as a result 
of EMT”. Biddle et al. claim “cancer stem cells…switch between an epithelial 
phenotype that drives tumour growth and an EMT phenotype that drives 
metastasis”. Kasimir-Bauer et al. state that “CTC [Circulating Tumor Cells], 
EMT and ALDH1 expression was not correlated to any of the prognostic 
clinical markers”; circulating tumor cells are cancer stem cells found in the 
circulatory system. 
 Recurrence correlates with another phenomenon, the tumor-initiating 
cell (or the cancer stem cell, CSC) (Saha, Lo, Duan, Chen, & Wang, 2012). 
Discovery of this subtype of cancer cells was a result of experimental 
practices. In theory, if every cancer cell has the potential to initiate a new 
tumor, only a small number of cells should be needed to initiate a tumor in an 
animal model. Reality is quite different. Initiating tumors in mouse models, 
even nude mice (which have a severely inhibited immune system), usually 
requires the injection of a few tens of thousands of cells. This implies that 
only a small percentage of cancer cells are capable of tumorigenesis (Bonnet 
& Dick, 1997). These are also the cells most likely responsible for relapse 
after treatment. 
 The defining characteristics of a cancer stem cell, besides tumorigenic 
capability, are self-renewal and pluripotency. Important genes are Notch, 
Wnt, and Bmi-1 (DiMeo et al., 2009; Martin & Cano, 2010; McAuliffe et al., 
 8 
2012). In addition, CSCs may display certain cell surface markers dependent 
on their organ of origin. 
 Studying how cancer stem cells develop is essential because CSC-
specific treatments would treat not only the present disease, but also the 
threat of recurrence. CSC-specific treatments could be used in conjunction 
with surgery for resectable tumors, thus lowering the risk of relapse and 
extending disease-free survival. One important distinction must be made: 
while cancer stem cells must (by definition) have tumorigenic potential, they 
are not necessarily the tumor-initiating cell in the primary tumor. 
 What is the connection between cancer stem cells and epithelial to 
mesenchymal transition? Some researchers assert that EMT is part of the 
process for generating CSCs, others assert that CSCs undergo EMT to 
become metastatic cells, and finally, some assert that they are opposing but 
complementary processes (Izumiya et al., 2012; May et al., 2011; Wu & 
Zhou, 2010). Here the important pathways and proteins associated with them 
will be explored to further elucidate the connection between them. A better 
understanding of signaling pathways and their interconnectedness may 
provide a guide to potential therapeutic and future research opportunities. 
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Published data 
 
EMT 
 Epithelial to mesenchymal transition describes a non-linear 
progression of a cell from a polar, differentiated, and adherent state (an 
epithelial phenotype) to an apolar, dedifferentiated, and motile state 
(mesenchymal phenotype). Mesenchymal to epithelial transition is the 
inverse and is a common process during development and wound healing 
(Savagner et al., 1997). 
 The exact role EMT plays in cancer progression is most likely the 
evolution from primary tumor to metastatic cancer (Garber, 2008). While 
some transcrlption factors involved with EMT play a part in initial 
tumorigenesis, EMT itself drives cells toward a metastatic phenotype 
(Garber, 2008). Thus, understanding EMT will enable us to treat patients in a 
more individualized fashion. While patients are already given treatment 
according to the type and stage of a tumor, being able to screen tumors 
based on EMT will provide a more accurate prognosis and may inform how 
aggressive treatment needs to be. First, we must consider, what defines the 
transition from epithelial to mesenchymal?  
 Classic oncogenic pathways may induce EMT (Serova et al., 2010; Z. 
Wang, Li, Kong, & Sarkar, 2010). Ras, which mediates cell growth and 
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survival, is known to activate Snail and Slug (Horiguchi et al., 2009); Snail 
and Slug are important transcriptions which promote a non-adherent 
phenotype. They will be discussed in greater depth later. 
External factors that induce or advance EMT are hypoxia, the rigidity 
and composition of the extracellular matrix, cytotoxic therapy and reactive 
oxygen species (Du et al., 2012; Fukawa, Kajiya, Ozeki, Ikebe, & Okabe, 
2012; Li et al., 2011; Markowski, Brown, & Barker, 2012). There is also 
growing evidence that microRNAs may play a part in EMT, thus external 
factors that change miRNA expression would also play a role in EMT (Ahn et 
al., 2012; Moes et al., 2012; Turcatel, Rubin, El-Hashash, & Warburton, 
2012). 
 Like tumorigenesis, there is no one single pathway responsible for 
EMT. There are multiple parallel pathways and more than one may be 
activated. In addition, a pathway that is important in pancreatic cancer may 
have no response in liver cancer. Thus a truly detailed study of EMT will 
involve studying the tumors of each organ separately. At the same time, 
there are pathways that are close to universally important, which will be 
discussed here. 
 
 
Classifying epithelial versus mesenchymal 
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First, what exactly defines an ‘epithelial’ phenotype versus a 
‘mesenchymal’ phenotype? As mentioned previously, we can define 
‘epithelial’ either through gene expression or through histological changes. 
Projected protein expression can be determined through quantitating mRNA 
levels using QRT-PCR (measuring mRNA levels using fluorescence), protein 
levels through Western blots, or using antibodies to visualize proteins on 
tissue sections through immunohistochemical staining. However, 
quantitatively determining EMT through gene expression becomes difficult. 
Basing the characterization on 2 to 3 genes oversimplifies the phenomenon. 
Gene signatures are becoming more prevalent to determine the EMT status 
of the tumor. 
Figure 2 shows the histological and molecular changes that exemplify 
EMT. ‘Fibroblast-like morphology’ means mesenchymal cells have a spindle 
shape (Figure 3, left panel). Also critical is the loss of E-cadherin, a 
membrane protein that mediates cell-cell adhesion. Loss of E-cadherin is 
linked with tumor progression in most solid tumors (i.e. breast, gastric, 
colorectal, thyroid, and ovarian), since decreased adhesion means the cell is 
more likely to become invasive (Tian et al., 2011; Yagasaki, Noguchi, 
Minami, & Earashi, 1996). Most of the other changes in EMT contribute to 
motility. Cytokeratins (also known as keratin intermediate filaments) attach to 
desmosomes and hemidesmosomes, thus mediating cell-to-cell and cell-to-
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basement-membrane adhesion (Franke, Kapprell, & Cowin, 1987). 
Plakoglobin, or gamma-catenin, is also part of cell adhesion junctions, where 
it associates with E-cadherin (Franke et al., 1987). 
In contrast to cytokeratin, vimentin is an intermediate filament 
associated with the mesenchymal phenotype. Until recently, the exact role of 
vimentin in EMT was not well understood, but we now know that vimentin 
expression is necessary for both cell motility and the spindle morphology 
(Hallman, Zhuang, & Schnellmann, 2008). Another factor in gaining motility 
are matrix metalloproteinases (MMPs), especially MMP2 (Peinado, Olmeda, 
& Cano, 2007). MMPs are extracellular or membrane-bound endopeptidases 
that degrade ECM proteins. MMP2 in particular degrades collagen IV, a 
major component of basement membranes. The composition of the ECM is 
also an important driver of EMT, as mesenchymal cells produce fibronectin, 
which causes a positive feedback loop that promotes EMT (Ding, 
Gelfenbeyn, Freire-de-Lima, Handa, & Hakomori, 2012; Freire-de-Lima et al., 
2011). Finally, N-cadherin is an important component of invasiveness. N-
cadherin mediates endothelial transmigration (Kamikihara et al., 2012), 
enabling cancer cells to move between endothelial cells in blood vessels, 
thus enabling escape from the primary tumor site and entry into another 
organ.  
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 Defining quantitative parameters that encapsulate EMT is much more 
difficult. Loss of E-cadherin and gain of vimentin have both been correlated 
with increased recurrence – in general (Yagasaki et al., 1996). One study of 
cervical cancer found high E-cadherin was positively correlated with survival 
recurrence and high vimentin expression was inversely correlated with 
survival and recurrence (Y. Cheng et al., 2012). In a study of breast cancer, 
expression of neither E-cadherin nor vimentin correlated with survival or 
recurrence – but co-expression of both was correlated with recurrence 
(Kallergi et al., 2011). The lesson is that each type of tumor behaves 
differently and any reliable diagnostic test will be specific to one type of 
neoplasm. 
 Most tests have been reverse engineered from analyzing either 
human cancer cell lines or human tumor samples (or both). This means 
researchers are able to identify which genes correlate with metastasis, 
progression-free survival, stage, and TNM status. However, the accuracy of 
such diagnostic tests is yet to be determined when applied on an individual 
basis. 
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Cancer stem cells 
 Cancer stem cells were first identified in 1997 as a subtype of 
leukemic cells that were capable of initiating tumors in nude mice (Bonnet & 
Dick, 1997). Since then, cancer stem cells have been found in many solid 
tumors including breast, colon, ovary, and pancreas (and other cancers). 
 Like EMT, classification of CSCs can be done using gene expression 
data. Unlike EMT, there are often cell surface markers that help distinguish a 
cancer stem cell from a ‘normal’ cancer cell; these markers are specific to the 
organ of origin, however. A common assay used to identify the amount or 
percentage of cancer stem cells in a sample is the spheroid formation assay. 
Cells are cultured in suspension and the number of spheroids that develop 
are correlated to the number of cancer stem cells. 
 Given their name, cancer stem cells share a number of characteristics 
with stem cells. Cancer stem cells are capable of self-renewal, which means 
that when they undergo mitosis, the daughter cells are identical to the mother 
cell (Grotenhuis, Wijnhoven, & Van Lanschot, 2012). They are also capable 
of differentiation, especially along multiple paths. Thus, when a stem cell 
divides it may produce more stem cells or what is called a progenitor cell (or 
one of each). A progenitor cell is a cell that is committed to a path of 
differentiation but has not yet finished the process of differentiation. A 
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progenitor cell may itself divide, but the daughters of progenitor cells will not 
have any stem-like properties. 
 Finally, and most importantly, stem cells are truly immortal. They are 
not subject to the Hayflick Limit. The Hayflick Limit means that non-stem, 
non-cancerous cells will divide a certain amount of times before becoming 
incapable of further division and replication (Hayflick & Moorhead, 1961). 
This is due to shortening of telomeres (repeated sequences which protect the 
ends of chromosomes) and can be reversed by activation of telomerase, an 
enzyme important to cancer progression (Holt, Wright, & Shay, 1996). This 
insusceptibility to the normal strictures of cell lifespan is what makes stem 
cells so powerful and, conversely, cancer stem cells so dangerous. 
Researchers believe that by targeting cancer stem cells, we may eradicate 
the whole tumor as well as the threat of metastasis and recurrence. 
 The origin of cancer stem cells is still debated. The main point of 
contention is whether they are stem cells that have become cancerous or 
cancer cells that have acquired ‘stem-ness’. The three possible paths are 
shown in Figure 4. It shows there are three possible origins for a cancer stem 
cell. The first shows a stem cell acquiring a mutation such that replication is 
constitutively ‘on’, thus becoming a cancer stem cell. The second shows a 
progenitor cell losing normal cell cycle regulation in addition to gaining self-
renewal. The third pathway depicts a normal, terminally differentiated cell 
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gaining ‘stem-ness’ and self-renewal. It is not yet clear which pathway (or 
pathways) generate cancer stem cells in vivo. It may be that all three can 
contribute, although not necessarily equally. 
 There is also a theory that within a tumor, multiple cell subtypes exist 
in equilibrium. A cell of subtype A can become a cell of subtype B or C, or 
any other configuration. The process is stochastic and can be modeled using 
a Markov process. Figure 5 illustrates this theory. It shows that when cell 
subtypes are separated, they begin moving back towards equilibrium, which 
consists of all three subtypes. This behavior is analogous to that of a 
balanced chemical reaction in equilibrium, but stochastically. 
 
 
Molecular markers of cancer stem cells 
 Cancer stem cells, unlike mesenchymal cells, cannot be identified 
using bright field microscopy; flow cytometry or QRT-PCR must be used (or 
less commonly, Western blots). Table 2 shows the cell surface markers that 
identify the subpopulation. These subpopulations are enriched in CSCs. For 
example, CD133+ colon cancer cells are 200-fold enriched with tumor-
initiating cells as compared to the whole population of colon cancer cells 
(O’Brien, Pollett, Gallinger, & Dick, 2007). While the amount of enrichment 
varies, many cancers have similar subpopulations that are enriched with 
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tumor-initiating cells. The cell surface markers listed in Table 2 represent a 
population that is more likely to contain cancer stem cells, rather than being 
markers for the CSCs themselves. 
 There are two potential explanations for why the subpopulation is only 
enriched with CSCs, rather than consisting entirely of CSCs. One is that the 
CSC-enriched subpopulation has some stem-like properties, but is still 
subject to the Hayflick limit. A final switch is necessary to become a tumor-
initiating cell. This theory is illustrated in Figure 6. The other potential 
explanation is that the common assay used to identify cancer stem cells 
(sphere-forming assay) is too stringent and leads to consistent 
underestimation of the amount of cancer stem cells. Undoubtedly, further 
research on what else separates cancer stem cells from normal cancer cells 
will elucidate the matter. 
 Table 2, also indicates that some cell surface markers are of 
consequence in multiple cancers. CD44 is implicated in 4 out of the 5 
cancers listed. CD133 is implicated in 2, as is CD24. CD24, however, is a 
positive marker in pancreatic cancer and a negative marker in breast cancer. 
This makes it harder to identify whether it should be positively or negatively 
correlated with the presence of cancer stem cells. 
 CD44 is involved in cell-cell interactions and cell adhesion to the 
extracellular matrix. It is also involved in migration and tumor metastasis. 
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CD44 has many splice variants, including one that directs cells to migrate to 
the bone marrow. CD44 binds to hyaluronic acid, an extracellular matrix (the 
space around and between cells) component. Other splice variants can bind 
to matrix metalloproteinases, collagens, fibronectin, and laminin – all of which 
are involved in EMT (Dimitroff, Lee, Rafii, Fuhlbrigge, & Sackstein, 2001; 
Goodison, Urquidi, & Tarin, 1999; Thomas, Zhu, Schnaar, Alves, & 
Konstantopoulos, 2008). Bivatuzumab, an anti-CD44 (v6) antibody, is linked 
with radioisotopes and used for radiotherapy in metastatic or recurrent head 
and neck cancer (Börjesson et al., 2003). 
 CD133 is a transmembrane protein that is also a stem cell marker. It is 
expressed in hematopoietic stem cells, glial stem cells, and endothelial stem 
cells (Corbeil, Fargeas, & Huttner, 2001; Yin et al., 1997). It localizes among 
cellular protrusions but its exact role in signaling is not clear. As Table 2 
shows, it is implicated in several cancers as a cancer stem cell marker. It is 
not currently a target of any therapeutic drugs. 
 CD24 is a cell adhesion molecule normally located on granulocytes 
and most B lymphocytes (Pirruccello & LeBien, 1986). When the B 
lymphocytes mature into plasma cells (antibody producing cells) they lose 
CD24 expression. A CD24 alanine to valine polymorphism has been 
implicated in susceptibility to and progression of multiple sclerosis, possibly 
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through changing efficiency of expression and T cell signaling (Ronaghi, 
Vallian, & Etemadifar, 2009). 
 
 
Transforming growth factor-beta 
 Transforming growth factor beta (TGF-β) is an autocrine and paracrine 
cytokine whose receptor is a receptor tyrosine kinase (RTK). There are three 
members (TGF-β 1, 2, and 3), each with a similar structure. In additional to a 
signal peptide, TGF-β also has a region called the latency-associated 
peptide (LAP) which is cleaved from TGF-β to produce the final protein. After 
TGF-β is secreted from the cell, it binds to both the LAP peptide and latent 
TGF-β binding protein. TGF-β is only released (and active) after proteolytic 
cleavage, usually by macrophages. TGF-β then dimerizes and binds to two 
TGF-β receptors, which phosphorylate each other (Figure 7) (Khalil, 1999). 
 TGF-β activates the Smad pathway by binding to TGF-β receptor II, 
which recruits TGF-β receptor I (and also phosphorylates it). The Smad 
pathway eventually results in formation of a heterodimer, which acts as a 
transcription factor; the R-SMAD and SMAD4 heterodimer activate the 
mitogen activating protein kinase 8 (MAPK 8) pathway (which is a pro-
apoptotic pathway). However, the Smad pathway is only one of many 
activated by TGF-β (Figure 7) (Khalil, 1999). 
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TGF-β controls pathways important to inflammation, wound healing, 
and cell cycle regulation (among others). Phosphoinositide 3-Kinase (PI3K) 
phosphorylates phosphatidylinositol, which then itself activates a number of 
pathways. The most important is the PI3K/AKT/mTOR pathway. mTOR 
regulates cell growth, motility, and cell metabolism. PI3K is also responsible 
for cancer cells’ insensitivity to glucose and IGF1. 
Normally, TGF-β inhibits growth through apoptosis as well as blocking 
cell cycle progression. Specifically, TGF-β stops the cell from leaving G1 
(and entering S phase, which normally commits the cell to mitosis) by 
blocking the cyclin and CDK complex from forming (Hanahan & Weinberg, 
2000). Thus, TGF-β signaling in healthy tissue results in an absence of 
proliferation and/or apoptosis. 
In Figure 8, we see that TGF-β can (normally) recruit macrophages 
but causes immunosuppression. Macrophage recruitment is part of the 
wound healing process. But TGF-β also converts effector T cells (which 
induce a robust immune response) into regulatory T cells (which suppress an 
immune response) (Ranges, Figari, Espevik, & Palladino, 1987). TGF-β also 
promotes angiogenesis, a process necessary for wound healing and tumor 
growth (Folkman & Klagsbrun, 1987). 
Significantly, there is a diametric shift in the role of TGF-β plays in 
normal tissue versus a metastatic cancer. Normally, TGF-β inhibits growth, 
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induces differentiation, and triggers apoptosis. But in an advanced tumor, 
TGF-β can be one of the driving factors behind metastasis. What induces 
this change? 
In early stage tumorigenesis, TGF-β has an inhibitory effect, through 
cyclin-dependent kinase inhibitors (Figure 8). As the carcinoma progresses, 
the cells eventually become refractory to the growth inhibitory effects. 
However, TGF-β signaling remains high and the other effects become central 
to the process of EMT (Figure 8). The acquired unresponsiveness to TGF-β 
signaling is more likely to be the result of multiple changes to the 
downstream pathways, rather than mutations in the TGF-β receptors (Blobe, 
Schiemann, & Lodish, 2000). 
Some tumors remain sensitive to TGF-β signaling, but many do not. 
The tumors that are refractory to TGF-β signaling benefit from the tumor-
promoting effects of TGF-β: immune suppression, ECM and fibroblast 
signaling, and promotion of EMT. In fact, in vitro addition of TGF-β can be 
sufficient to cause EMT in some human cancer cell lines (Turcatel et al., 
2012; J. Zhang et al., 2012). 
 
Reactive oxygen species 
 Reactive oxygen species (ROS) also play a role in the progression of 
EMT (Murphy, 2009). ROS are a natural byproduct of metabolism and 
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originate mainly from the mitochondria. Figure 9 shows the creation of ROS 
as electrons from the electron transport chain in the mitochondria. Electrons 
released from the electron transport chain combine with an oxygen molecule 
to form a superoxide anion. The superoxide molecule is converted by 
superoxide dismutase into peroxide. Peroxide is then converted to form 
water. Peroxide can also be eliminated by peroxiredoxins, catalase, and 
glutathione peroxidase. 
 Reactive oxygen species have been linked to aging. Animals in which 
the ROS eliminating enzymes have been downregulated or knocked out 
have a reduced lifespan – but the inverse is not true (consistently). As ROS 
are mainly generated in the mitochondria, most of the damage done is to the 
mitochondria as well (Muller, Lustgarten, Jang, Richardson, & Van Remmen, 
2007). But if the ROS escape into the cytoplasm, they may not only oxidize 
cytoplasmic proteins but also enter the nucleus and damage cellular DNA.  
At normal levels, ROS are eliminated by SOD2 in the mitochondrion 
but when ROS damage reaches a certain threshold, programmed cell death 
or apoptotic pathways are activated via the Bax group of proteins. They 
puncture the mitochondrial membrane, so that cytochrome C enters the 
cytoplasm and activates apoptotic protease activating factor-1 (APAF-1). The 
cytochrome C and APAF-1 aggregates activate caspase 9 (Figure 10). 
Caspase 9 activates caspases 3 and 7, which then activate apoptosis itself. 
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However, in cancer cells normal apoptotic pathways have been 
inactivated, thus damage from ROS cannot promote apoptosis. So what role 
do ROS play in the progression of cancer? ROS (and reactive nitrogen 
species, RNS) act as signaling molecules for several pathways. In particular, 
extracellular ROS promote EMT by upregulating TGF-β (Fukawa et al., 
2012). ROS are also thought to be involved in intracellular signaling, 
specifically in activating the ERK/MAPK pathway. Administration of TGF-β 
concurrently with antioxidants (versus just TGF-β) resulted in downregulated 
ERK, as well as reducing EMT (Fukawa et al., 2012). 
The main role that ROS plays is most likely in the extracellular 
environment. Specifically, extracellular ROS are mostly released by cancer-
associated fibroblasts (CAF) (Giannoni, Bianchini, Calorini, & Chiarugi, 
2011). Cancer-associated fibroblasts, among other roles, provide high-
energy molecules like lactate and pyruvate. This phenomenon is called the 
Reverse Warburg Effect (Pavlides et al., 2009) and can be measured 
specifically through loss of caveolin-1, a scaffolding protein and tumor 
suppressor gene (Lisanti et al., 2010). Loss of caveolin-1 strongly correlates 
with metastasis, drug resistance, and recurrence. In triple-negative breast 
cancer, patients with high caveolin-1 expression had 75% survival at 12 
years versus 10% survival at 5 years for patients with low caveolin-1 
expression (Witkiewicz et al., 2009, 2010).  
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Caveolin-1 is downregulated by hypoxia via ROS which then 
upregulates HIF-1α (Y. Wang et al., 2012). These factors induce autophagy 
in the cancer stroma, the result being that the self-digesting fibroblasts 
produce nutrients for the cancer cells (Lisanti et al., 2010). Given that many 
tumors are hypoxic, this enables the tumor cells to survive until metastasis or 
angiogenesis results in normoxia. Interestingly, upregulation of autophagy in 
the tumor stroma seems to protect the tumor cells themselves against 
apoptosis (Martinez-Outschoorn et al., 2010). 
The ROS released by CAFs have multiple roles, one being 
upregulating inflammatory pathways. As mentioned, TGF-β is activated by 
ROS, as is tumor necrosis factor (TNF) and the inflammatory interleukins 
(IL). Bone morphogenetic protein (BMP) and NADPH oxidase 1 also use 
ROS to upregulate matrix metalloproteinase 2 (MMP2), which increases the 
mobility of the cell and contributes to ECM remodeling (Kobayashi & Suda, 
2012). In general, the “pro-inflammatory signature” released by cancer-
associated fibroblasts is beneficial to the cancer cells, as it stimulates growth. 
Figure 11 shows multiple pathways in which ROS are also implicated. 
While ROS upregulate EMT, they are deleterious to cancer stem cells 
(Kobayashi & Suda, 2012). Since stem cells must have self-renewal, they 
must also live in low ROS environments. Thus rather than ROS promoting 
progression (as it does for EMT), high ROS are harmful to CSCs. FoxO3, a 
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transcription factor regulated by the PI3K/Akt pathway, upregulates SOD2 
and catalase expression when unphosphorylated. Thus, FoxO3 knockout 
mice have higher levels of ROS compared to wild type mice and their 
hematopoietic stem cells (HSC) “exhibit hyper-proliferation that leads to HSC 
pool exhaustion in the bone marrow” (Shi, Zhang, Zheng, & Pan, 2012). 
Treatment with n-acetylcysteine, an antioxidant, results in the pool being 
replenished. 
This behavior is also true for cancer stem cells. Treatment with 
niclosamide and parthenolide (both ROS-increasing agents) can induce 
apoptosis in AML stem cells via an increase in ROS (Shi et al., 2012). 
However, exactly why ROS cause cell death is not clear. It may be via the 
traditional pathways of DNA/protein damage or it may be that high levels of 
ROS induce differentiation, thus negating the self-renewal properties of a 
cancer stem cell. The latter hypothesis is supported by the ‘multiple groups in 
equilibrium’ theory illustrated in Figure 5, as high ROS may favor formation of 
differentiated cancer cells versus stem-like cancer cells. 
Unfortunately, there is very little published research on the role of 
ROS in cancer stem cells – but as time passes, more information will clarify 
whether antioxidant or prooxidant therapy is more effective in treating cancer. 
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Twist 
 Twist is a helix-loop-helix transcription factor that is also an oncogene 
(Bourgeois, Stoetzel, Bolcato-Bellemin, Mattei, & Perrin-Schmitt, 1996; 
Puisieux, Valsesia-Wittmann, & Ansieau, 2006). Twist has strong 
associations with metastasis, EMT, and apoptosis/adjuvant resistance 
(Puisieux et al., 2006). Twist is also a major factor in embryonic 
morphogenesis. Specifically, lack of Twist expression results in failure of the 
cephalic neural tube to close. Neural crest cells also do not migrate and 
differentiate correctly, resulting in malformation of the brachial arches (Soo et 
al., 2002). 
 HIF-1α upregulates Twist, another important transcription factor for 
EMT (Figure 12) (M.-H. Yang & Wu, 2008). HIF-1α is upregulated in 
response to hypoxia. Twist downregulates E-cadherin and upregulates matrix 
metalloproteinases, specifically MMP2 and MMP9 (X. Zhao et al., 2011). The 
loss of adhesion and gain of ECM remodeling enzymes promotes a mobile 
and metastatic phenotype. In addition, there is evidence that Twist facilitates 
β-integrin independent extravasation, thus increasing the chance of 
successful metastasis (Stoletov et al., 2010). 
 Twist, when upregulated, also increases both the ‘stemness’ and 
resistance to apoptosis. In breast cancer cells, upregulation of Twist 
promotes formation of the CD44high/CD24low population that characterizes 
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breast cancer stem cells. The acquisition of the cell surface markers is 
“independent of the EMT” (Kallergi et al., 2011; Tran, Corsa, Biswas, Aft, & 
Longmore, 2011). The Twist-overexpressing population exhibits two 
important features of stemness: transporters that confer drug resistance and 
tumorigenicity. Only twenty cells were needed to generate a tumor in SCID 
mice (Vesuna, Lisok, Kimble, & Raman, 2009). As usual protocols call for 
hundreds of thousands of cells, this is a shockingly low number; this 
suggests a nearly pure population of cancer stem cells. 
 Twist also protects against apoptosis, especially when induced by 
chemotherapeutic agents. When treated with cisplatin, taxol, and 
cyclohexamide, cancer cells were less likely to apoptose when Twist was 
overexpressed (Latifi et al., 2011; Li et al., 2011; X. Zhang et al., 2007). In 
addition, an shRNA targeted to Twist increased cells’ sensitivity to cisplatin 
(Latifi et al., 2011). In the case of taxol resistance, the underlying mechanism 
may involve Bcl (an oncogene implicated in chronic myeloid leukemia) (X. 
Zhang et al., 2007). However, this has only been demonstrated in one cell 
line. Twist also protects against apoptosis in fibroblasts during fibrosis 
(Bridges et al., 2009). While this may seem unrelated, fibrosis is 
characterized by a similar inflammatory gene signature; this involves 
upregulation of inflammatory cytokines and recruitment of the immune 
system. 
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 Finally, Twist is important to cell cycle regulation and preventing 
anoikis. Anoikis, apoptosis induced by detachment from the extracellular 
matrix, is something tumor cells must escape to successfully metastasize. 
Detachment normally causes apoptosis since cells are dependent on 
extracellular growth signals. Tumor cells, however, must produce their own 
growth signals (or turn the pathway constitutively ‘on’) in order to survive. 
Twist is part of this process, in concert with Snail (Montserrat et al., 2011). In 
human embryonic stem cells, loss of the cell cycle inhibitor p27(Kip)1 causes 
upregulation of Twist as well as gain of self-renewal capabilities (Menchón, 
Edel, & Izpisua Belmonte, 2011). 
 
 
Snail and Slug 
 Snail and Slug are also transcription factors in the zinc finger family. 
The Snail family of transcription factors bind to the E box, the same binding 
site that is favored by helix-loop-helix transcription factors like Twist (Cohen 
et al., 1998; Paznekas, Okajima, Schertzer, Wood, & Jabs, 1999). Like Twist, 
Snail and Slug are involved in neural crest formation and migration during 
embryonic development; they also act downstream of TGF-β (Harney, 
Meade, & LaBonne, 2012). Snail’s direct target is E-cadherin – Snail 
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overexpression directly causes E-cadherin repression (Cano et al., 2000; 
Dave et al., 2011). 
 In addition to E-cadherin repression, Snail overexpression causes 
repression of desmoplakin and upregulation of vimentin and fibronectin 
(Cano et al., 2000). The first is an adhesion molecule and the latter two are 
common markers of mesenchymal cells. These changes are truly the result 
of Snail overexpression “as transfection of E-cadherin is not enough to 
induce a reversion to an epithelial morphology” (Nieto, 2002). 
 Like Twist, Snail and Slug appear to be essential for the transition 
from epithelial and adhesive to mesenchymal, motile and invasive (Figure 
13). By downregulating E-cadherin, Snail and Slug flip (what is considered) 
the main switch to transition the cell from epithelial to mesenchymal. But they 
also influence the motility and stemness of the cell (Figure 14). 
 Snail and Slug also confer resistance to apoptosis and anti-cancer 
agents. When Snail or Slug expression was reduced (via shRNA), cell lines’ 
sensitivity to drugs (i.e. cisplatin, gefinitib) was increased (Chang et al., 2011; 
Latifi et al., 2011). Cells were also less likely to apoptose after treatment with 
such drugs. 
 Snail and Slug are strong indicators for mortality, especially in breast 
cancer (Tran et al., 2011). One study of hepatocellular carcinoma found that 
positive staining of Slug correlated with tumor recurrence (Woo et al., 2011). 
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Another study of gastric cancer found that Snail correlated with lymph node 
metastasis and vascular invasion (along with E-cadherin, vimentin, and 
CD44) (Ryu, Park, Kim, Kim, & Lee, 2012). Interestingly, expression 
analyses of these four genes also “predicted disease-free survival 
independent of pTNM stage and histologic differentiation” (Ryu et al., 2012). 
Increased Snail expression in pharyngeal squamous cell carcinoma 
predicted disease specific survival. Snail expression in the tumor stromal 
myofibroblasts may also be a predictor of survival, adding credence to the 
importance of the CAFs (Jouppila-Mättö et al., 2011). 
 Snail upregulates expression of NanoG, a gene that is critical for 
conferring stem-like properties (Izumiya et al., 2012). NanoG is one of a four 
gene set used to create viable induced pluripotent stem cells (the other three 
being Oct4, Sox2, and Lin28) (Yu et al., 2007). Snail overexpression also 
induces stem-like traits in a human squamous tongue carcinoma; these traits 
include “low proliferation, self-renewal, and CSC-like markers expression” 
(Zhu et al., 2012). Upstream signaling molecules that are responsible include 
TGF-β and HIF-2α. 
 In general, Snail and Slug are extremely important to EMT. They are 
the main repressors of E-cadherin, along with Zeb-1 (another mesenchymal 
transcription factor). They not only help cells acquire mesenchymal traits, 
they also cause acquisition of stem-like properties. They appear to be 
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important to formation of cancer stem cells (as well as EMT); thus, they are 
excellent therapeutic targets as successful inhibitions may prevent both 
metastasis and recurrence. 
 
 
Extracellular matrix and tumor stroma 
 The stroma and extracellular matrix (ECM) are the support systems 
that enable cells of a particular organ to perform their function.  Their role can 
be mechanical, biological, or both. The extracellular matrix is biological 
scaffolding. The main ECM protein is collagen, which has 28 (and counting) 
different subtypes. Other important proteins are laminin, elastin, and 
fibronectin. These are the fibrous components of the ECM. The other 
components are glycosoaminoglycans, polysaccharides, and proteoglycans. 
The fibrous and soluble components create a hydrogel that can withstand 
mechanical stress while letting small molecules and nutrients diffuse through 
(Lodish et al., 1999). 
 Stromal cells comprise the connective tissue that supports the 
parenchyma. Fibroblasts are one common example of stromal cells and the 
type most relevant to tumor progression. In addition to producing the 
materials that comprise the ECM, fibroblasts manipulate the composition of 
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the microenvironment in order to cause or suppress growth and senescence 
(Lodish et al., 1999). 
Until recently, it was thought that fibroblasts used oxidative 
phosphorylation to generate energy while tumor cells used aerobic 
glycolysis. This was called the Warburg effect. In 2009, the reverse Warburg 
effect was postulated; tumor cells use their mitochondria to generate energy 
while releasing ROS under normoxic conditions to stimulate fibroblasts into 
using aerobic glycolysis (Pavlides et al., 2009). This theory explains why loss 
of caveolin-1 expression is damaging to disease-free survival. Caveolin-1 is a 
scaffolding protein that collects and condenses cell membrane signaling 
molecules. Loss of caveolin-1 causes autophagy and loss of mitochondria in 
the fibroblasts (Capparelli et al., 2012). Figure 15 depicts this harmful 
feedback cycle. 
Downregulation of caveolin-1 leads to oxidative stress and autophagy, 
which increase the ROS in the microenvironment. As mentioned before, this 
maintains an inflammatory profile in addition to doing DNA damage to the 
tumor cells; the DNA damage may help generate novel mutations (or it may 
kill the tumor cell, which is why some have suggested using prooxidant 
compounds to treat tumors). As oxidative stress increases, the fibroblasts 
undergo autophagy and eventually release ketones, lactones, and various 
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other nutrients into the ECM. The cancer cells may then use these high-
energy molecules to fuel their growth (Pavlides et al., 2009). 
 The interaction between tumor cells and stromal cells is bidirectional, 
as illustrated by Figure 15. Tumor cells can manipulate stromal cells into 
producing a more conducive environment for the tumor cells, but stromal 
cells can also increase the chance of tumorigenesis in normal epithelial cells. 
Research has shown that irradiated mammary stroma can increase the risk 
of carcinomas developing out of normal mammary epithelial cells. This may 
happen through “Mutations…specifically regulating paracrine growth factor 
expression” (Bhowmick & Moses, 2005). Irradiated stroma can also increase 
the aggressiveness of an existing carcinoma. 
 The same bidirectional influence exists between ECM proteins and 
tumor cells, although the interactions are less nuanced. One factor that 
induces EMT is stiffness – although including fibronectin fragments that 
engage with α3 and α5 integrins can mitigate the effect (Markowski et al., 
2012). ECM stiffness also changes the response of growth factor pathways; 
in a stiffer matrix the response to exogenous TGF-β was EMT but in a softer 
matrix, the response was apoptosis. The change in response was mediated 
through the PI3K/Akt pathway (Smad-independent) (Leight, Wozniak, Chen, 
Lynch, & Chen, 2012). 
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 Collagen I also upregulates EMT (in prostate and ovarian cancer cell 
lines) and stemness (in a colorectal cancer cell line) and downregulates E-
cadherin in all three (J.-C. Cheng & Leung, 2011; Kirkland, 2009). In prostate 
and ovarian cancer cells lines, collagen I upregulates Snail and Slug 
(transcriptional repressors of E-cadherin) via PIK3CA. In the colorectal 
cancer cell line, “effects were partially abrogated by a function-blocking 
antibody to α2 integrin”, suggesting a possible mechanism (Kirkland, 2009). 
Finally, a cancer stem cell-enriched population from a mouse breast cancer 
cell line was cultured on three different coated substrates: fibronectin, 
laminin, and collagen. Fibronectin stimulated an invasive phenotype while 
collagen effected differentiation. Laminin alone was able to maintain a stem-
like and self-renewing phenotype(Saha et al., 2012). 
 While upregulation of mesenchymal genes makes cells resistant to 
anoikis, it appears that cancer stem cells benefit from having ECM proteins 
to bind to. A CSC-enriched population of head and neck squamous 
carcinoma was cultured in suspension and plates coated with laminin, 
fibronectin and type IV collagen. The cells adhered to the type IV collagen 
coated plate grew most quickly; in general, the adherent cells were more 
stem-like than the cells in suspension. The adherent cells were less 
apoptotic, more resistant to chemotherapeutics (paclitaxel, cisplatin, 
docetaxel, and fluorouracil), and expressed higher levels of stem cell 
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markers Oct4 and CD44 (Lim, Oh, & Kim, 2012). Another paper found that 
hydroxyl radical-modified collagen was not favorable for CSC growth (Cipak 
et al., 2010). 
 
 
Wnt 
 The highly conserved Wnt signaling pathways are necessary for 
embryonic patterning, adult tissue maintenance, and wound healing. There 
are 19 human Wnt genes and 10 receptors that are part of the Wnt signaling 
pathways. For example, in embryonic development, a gradient of Wnt (and 
Sonic Hedgehog) helps guide correct development of the neural tube (Logan 
& Nusse, 2004). 
 Much of Wnt’s action in cancer seems to happen through the 
canonical β-catenin pathway (Nusse, 2005). Without Wnt signaling, β-catenin 
is more likely to be phosphorylated and degraded. In the presence of Wnt 
signaling, however, β-catenin is translocated to the nucleus and can activate 
transcription of certain genes while bound to transcription factors. β-catenin 
is known to interact with many genes, including two that are of interest in 
EMT. These include E-cadherin and plakoglobin (Y. Cheng et al., 2012). 
 β-catenin and E-cadherin interaction appears to be essential for 
“maintaining epithelial integrity”. This is because E-cadherin forms a complex 
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with β-catenin; the formation of the complex inhibits β-catenin from 
translocating into the nucleus (as E-cadherin is a transmembrane protein). 
Thus, high expression of E-cadherin means low β-catenin signaling. 
Disruption of E-cadherin expression in the course of tumor progression leads 
to higher β-catenin (and Wnt) signaling (Tian et al., 2011). 
 Wnt, via β-catenin, upregulates stem cell characteristics in cancer 
cells, including self-renewal and chemoresistance. A CD133+ population was 
isolated from neuroblastoma cell line and treated with a chemotherapy drug, 
doxycycline. Wnt expression was higher in CD133+ (compared to CD133- 
cells), with or without doxycycline treatment. Adding a Wnt pathway inhibitor 
increased the effectiveness of doxycycline in the CD133+ cells, suggesting 
that Wnt is the pathway responsible for chemoresistance (Vangipuram, Buck, 
& Lyman, 2012). Supporting this hypothesis, 5-fluorouracil, another 
chemotherapeutic agent, upregulates Wnt signaling in CD133+ colorectal 
cancer cells but not CD133- cells (Deng et al., 2010). 
 Wnt has been implicated in wound repair. Expression of Wnt-5a in the 
deep end of a cutaneous wound induced “changes…mimicking regeneration, 
including formation of epithelia-lined cysts in the wound dermis, rudimentary 
hair follicles and sebaceous glands, without formation of tumors” (Fathke et 
al., 2006). This suggests that Wnt may affect plasticity. In addition, 
successful establishment of a metastatic colony requires stromal secretion of 
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periostin, which upregulates Wnt signaling in cancer stem cells (Malanchi et 
al., 2012). 
 Finally, Wnt appears to regulate self-renewal in several types of 
cancer: gastric, lung, breast, and colorectal. Wnt and β-catenin also 
upregulate Zeb-1, a known mesenchymal gene; thus Wnt and β-catenin help 
drive epithelial to mesenchymal transition as well as self-renewal, plasticity, 
and chemoresistance (Kahlert et al., 2012; Ryu et al., 2012). 
 
 
microRNA 
 Since its discovery, RNA interference (RNAi) has proved to be an 
invaluable tool for research. Short hairpin RNAs (shRNA) or short interfering 
RNAs (siRNA) provide a way to knock down protein expression transiently 
and specifically. RNAi works at the level of translation and prevents protein 
translation either by causing destruction of the RNA transcript or preventing 
translation. Exogenous RNAi is referred to as siRNA or shRNA. Endogenous 
RNA is micro RNA (miRNA) and was first discovered in nematodes. 
 miRNA has since been implicated as an essential part of gene 
regulation in eukaryotes, including humans (Lee, Risom, & Strauss, 2007). 
Abnormal miRNA expression is associated with several diseases and as 
such offers potential therapeutic targets. Figure 16 shows how miRNAs work 
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– after transcription, the primary miRNA is processed by Drosha enzyme, 
then exported out of the nucleus into the cytosol. After further processing by 
Dicer, the miRNA binds to RNA-induced silencing complex, RISC (a protein 
complex), and then interacts with its target mRNA(s) (Hammond, 2005). 
 While exogenous siRNAs and shRNAs are designed to be as specific 
as possible, miRNAs may have several target genes. In addition, a gene may 
be the target of several miRNAs (Rajewsky, 2006). To illustrate this point, 
Table 1 miRNA has a list of miRNAs whose expression is altered by Zeb-1. 
Each of these miRNAs has at least one target gene; Table 1 miRNA 
illustrates the breadth and complexity of regulation that can be achieved. 
 Some miRNAs have been found to be oncogenic (“oncomirs”) while 
others suppress oncogenic proteins and are thus tumor suppressors (He et 
al., 2005; Mraz & Pospisilova, 2012). The miRNA-200 family is (among other 
genes) responsible for downregulating the E-cadherin repressor, Zeb-1. Zeb-
1, in turn, downregulates expression of miRNA 200 (mir-200) (Hill, Browne, & 
Tulchinsky, 2013). They form a feedback loop of mutual repression, 
illustrated in Figure 17. In the epithelial phenotype, mir-200 expression is 
high and represses Zeb-1. External stimulation of Zeb-1 expression 
(provided here by TGF-β) causes Zeb-1 to ‘turn off’ mir-200.  
 There is evidence that the mir-200/Zeb-1 loop is sufficient to switch a 
cell from an epithelial phenotype (E) to a mesenchymal (M) phenotype; 
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upregulating mir-200 expression in vivo may be sufficient to cause 
mesenchymal to epithelial transition (MET) thus making the tumor less likely 
to metastasize (Hill et al., 2013). Figure 18 demonstrates the regulatory loop 
enacted by Zeb-1, Zeb-2, Snail, and the miRNA 200 family. The graph at the 
bottom shows expression levels of all the proteins involved over the course 
of an E to M transition. 
 Mir-93, mir-302, and mir-372 are involved in pathways that produce 
cancer stem cells. Mir-93 reduces the presence of CSC characteristics while 
mir-302 and mir-372 do the opposite (S. Liu et al., 2012; Subramanyam et 
al., 2011, p. -93). There is less known about the role of miRNAs in the 
development of cancer stem cells, but as this is a highly active area of 
research, it will resolve itself in time. 
 RNAi holds great promise as a therapy for many diseases – if the 
issue of delivery can be solved. RNA that is injected into the tissue or 
bloodstream has an extremely short half-life, due to endogenous RNAses 
(C.-G. Liu, Calin, Volinia, & Croce, 2008). siRNA or shRNA can be delivered 
intracellularly using viral or eukaryotic vehicles. Lentiviruses are a common 
tool, as they insert the viral DNA into the host DNA (Tiscornia, Singer, Ikawa, 
& Verma, 2003). Eukaryotic cells can be removed from the host, transfected, 
and reinserted into the patient (N. Zhao, Fogg, Zechiedrich, & Zu, 2011). 
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Other methods of delivery include encapsulation in lipid spheres of various 
designs (Mokhtarieh, Cheong, Kim, Chung, & Lee, 2012). 
 Table 2 miRNA shows a number of clinical trials that used RNAi to 
treat cancer. The first row shows a drug targeted against β-catenin, 
discussed above in relation to Wnt. Other trials target VEGF (an angiogenic 
factor), PLK1 (a mitotic spindle-associated protein), RRM2 (creation of DNA 
bases), Mecl1, LMP2, and LMP7 (MHC subunits). 
 There are currently 13 clinical trials using siRNA/shRNA to treat 
cancer  (http://clinicaltrials.gov/). One Phase II trial for Stage III ovarian 
cancer uses a combination of Bevacizumab (an anti-VEGF-A antibody) and 
the FANG™ vaccine. The FANG™ vaccine expresses human granulocyte 
macrophage colony-stimulating factor (hGM-CSF) and an anti-Furin shRNA. 
The former recruits the immune system while the latter reduces TGF-β 
levels. Furin is a protease that activates both TGF-β1 and TGF-β2. Tumor 
cells are removed from the patient, electroporated with the vaccine, and then 
reinjected into the patient (Senzer et al., 2012). 
 Another trial for solid tumors involves administration of an anti-
ribonucleotide reductase siRNA encapsulated in a targeted nanoparticle. If 
successfully delivered, the siRNA will target only dividing cells as 
ribonucleotide reductase creates DNA bases from RNA bases (Eifler & 
Thaxton, 2011). 
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 One other therapeutic possibility is to use antagomirs instead of or in 
concert with RNAi. Antagomirs are short RNAs that bind to micro RNAs in 
vivo, such that the effect of the miRNA is abrogated or reduced (Krützfeldt et 
al., 2005). If a method of consistent and specific delivery for RNA oligomers 
is created, both antagomirs and siRNAs/shRNAs for multiple targets could be 
used in customizable mixes. Since natural miRNAs can have multiple 
targets, it may be preferable to use synthetic siRNAs in order to avoid 
unintended effects. 
 
 
Cytotoxic therapy 
 As mentioned in the introduction, there are currently four main 
therapies used in cancer treatment: surgery, radiation, cytotoxic drugs, and 
inhibitors. The last may be small molecules or antibodies. Cytotoxic drugs 
generally interfere with cell division, since many types of cancer cells are 
rapidly dividing. Side effects occurred because certain normal cells in the 
body are also dividing rapidly including hair follicle cells, cells in the gastric 
mucosa, immune cells, and erythroid progenitors (for example). 
Gastrointestinal distress and immunocompromisation are particularly serious 
side effects of chemotherapy that can (in acute cases) lead to the death of 
the patient (Joensuu, 2008). 
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 There are multiple cytotoxic agents and they have many different 
modes of action. Topoisomerase inhibitors interfere with DNA transcription 
and replication, while anti-metabolites affect DNA and RNA synthesis. 
Cytotoxic antibiotics generally cause massive DNA damage, as do platinum-
containing drugs (i.e. cisplatin, carboplatin). The final class of drugs are 
inhibitors that are used when a tumor has either a specific mutation or a 
higher than normal expression of a particular protein. For example, gefitinib 
is an epidermal growth factor receptor (EGFR) inhibitor and is most effective 
in tumors with high EFGR expression (“Chapter 3,” 2009). However, tumors 
can escape from these drugs and become resistant. There is evidence that 
the CSC population is responsible for acquisition of such resistance 
(Achuthan, Santhoshkumar, Prabhakar, Nair, & Pillai, 2011). 
 It is well established that cancer stem cells are chemoresistant. In 
addition, there is abundant evidence that having undergone EMT also 
increase chemoresistance (Izumiya et al., 2012; Latifi et al., 2011; W. Zhang 
et al., 2012; W.-L. Zhuo, Wang, Zhuo, Zhang, & Chen, 2008). This poses a 
problem since these cells are the root of metastases and recurrence. Two 
potential solutions are finding CSC-specific toxic agents and finding a way to 
effect MET or reverse acquisition of stem-like traits. Both avenues are being 
pursued and may make an excellent companion treatment to traditional 
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chemotherapeutics. For example, siRNA knockdown of Snail in breast 
cancer cells increased sensitivity to 5-fluorouracil (W. Zhuo et al., 2008). 
 There is also some evidence that cytotoxic agents may ‘push’ EMT or 
increase the chance of cancer stem cells developing. Cisplatin selectively 
enhances the CD133+ cell population in colorectal cancer through activation 
of the Notch pathway (Y.-P. Liu et al., 2013). CD133+ cells are the CSC-
abundant population in colorectal cancer (Table 2). It is unclear whether 
cisplatin specifically kills CD133- cells or shifts the equilibrium balance 
between the cancer stem cell and normal cancer cell subpopulations. EMT is 
also affected by chemotherapy; a study of clinical breast cancer found that 
patients that received cyclophosphamide, 5-fluorouracil, or epirubicin showed 
downregulation of mir-448, which then led to an increase in NF-κβ and Twist 
signaling (Li et al., 2011). 
 Since mesenchymal cells and cancer stem cells are chemoresistant, it 
may be that cytotoxic drugs appear to upregulate these phenotypes as 
‘regular’ tumor cells die off in response to the drug. One theory states that 
apoptotic mechanisms are even more damaged in CSCs and mesenchymal 
cells, so they can sustain greater levels of damage without suffering cell 
death (Sperka, Wang, & Rudolph, 2012). Most likely, the processes of 
acquiring chemoresistance and increasing mesenchymal propertiesand 
stemness are either the same or closely intertwined. A clinical study of 
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hepatocellular carcinoma treated with sunitinib revealed heterogeneity within 
the tumor; discrete portions of the tumor were more mesenchymal than other 
areas and perhaps were developing sunitinib resistance(Marijon et al., 2011). 
 
 
Discussion 
  
As a tumor progresses, the inflammatory signaling (both autocrine and 
paracrine) and hypoxia stimulate activation of several signaling pathways. 
Transcriptional repression of E-cadherin is the main switch that begins the 
process of converting adherent, polar, and differentiated cells into motile, 
apolar, and stem-like cells.  
 Zeb-1 and Zeb-2 are the main transcriptional repressors of E-cadherin 
and they, in turn, are upregulated by Snail. Under normal conditions, mir-200 
and mir-203 repress Snail, Zeb-1, and Zeb-2 (Figure 18). This feedback loop 
is the best pathway to target for treatment. There are multiple targets, which 
can be treated simultaneously: mir-200, mir-203, Zeb-1, Zeb-2, and Snail. 
Reversing the E-cadherin ‘switch’ will slow down (if not halt) tumor 
progression. Successful RNAi therapy would promote adherence and apico-
basal polarity; it would also help suppress invasion of the basement 
membrane, which is normally a critical step (in cancers of epithelial origin).  
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In the course of carcinoma progression, an external stimulus reverses 
the balance and mir-200 and mir-203 are now repressed by Snail and Zeb-
1/Zeb-2, which then repress E-cadherin transcription. Since E-cadherin 
normally complexes with β-catenin, repression of the former leads to release 
of the latter, which then activates Wnt signaling pathways. Wnt and β-
catenin, as discussed, promote stem cell related genes related to 
chemoresistance and self-renewal. Treating Wnt would make cancer stem 
cells more susceptible to standard cytotoxic therapy and help prevent 
recurrence. 
The TGF-β signaling pathway is another suitable target for treatment. 
While other growth factors play a role in stimulating tumorigenesis and 
cancer progression, TGF-β is singled out here due to its ubiquity and its role 
in stromal support. Reducing the amount of TGF-β present (or ‘released’) in 
the tumor stroma will suppress the inflammatory phenotype associated with 
CAFs. 
Cancer-associated fibroblast treatment should address both the 
reverse Warburg effect and production of extracellular matrix. Targeting 
aerobic glycolysis will remove an energy source and hopefully slow tumor 
growth. In addition, fibronectin production and ECM stiffness contribute to 
motility. Treating the tumor stroma may help eliminate the hypoxic, low ROS, 
collagen IV-filled niches that harbor cancer stem cells. 
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Since Snail and Slug upregulate Zeb-1, they are potential targets for 
the same reasons; they do, however, have other important effects. Snail can 
impart chemoresistance and upregulates NanoG (a stem cell gene). Twist 
also confers chemoresistance and apoptosis/anoikis resistance. Snail, Slug, 
and Twist all upregulate genes that strengthen the mesenchymal nature of 
the cell. Such qualities include: upregulation of vimentin, resistance to 
cytotoxic drugs, self-renewal, anoikis/apoptosis resistance. 
The goal of this thesis is to elucidate the connection between cancer 
stem cells and epithelial to mesenchymal transition. Does EMT lead to 
formation of cancer stem cells? Are they entirely separate phenomena? Are 
they opposite but complementary processes? 
There are clear links between mesenchymal genes and stem cell 
genes, enough that EMT and CSCs are positively correlated. They are not 
entirely unrelated nor are they opposite but complementary processes. 
Epithelial to mesenchymal transition upregulates genes that promote stem-
like behavior, thus easing the transition to becoming a cancer stem cell. 
Figure 1 Discussion is a visual representation of the concept. 
 In this model, EMT involves becoming more stem-like. EMT is the 
process that enriches the tumor population for potential cancer stem cells. 
Thus the tumor population consists of cells located on the ‘E’ to ‘M’ spectrum, 
with the ‘M’ end being enriched in cells that are, or might become, cancer 
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stem cells that are responsible for tumor recurrence. This could explain the 
phenomenon detailed in an earlier section; researchers have found 
populations of tumor cells (expressing certain cell surface markers) that are 
enriched in CSCs. As for why only some cells become cancer stem cells, it 
may be that equilibrium between the CSC and non-CSC must be maintained. 
It might be that only a few cells are likely to undergo the entire 
transformation. It may also be that the microenvironment required is too 
specialized to support more than the small amount of CSCs found in tumor 
cells. 
Most likely, it is a combination of the above reasons. Regardless, the 
signaling pathways involved in EMT and generating CSCs provide excellent 
targets for developing anti-cancer treatments. These future drugs may prove 
less harmful and eventually obviate the need for cytotoxic drugs (and 
perhaps even surgical resection of solid tumors). 
 
Conclusion 
 
If the signals that define an aggressive cancer can be identified, 
patient-specific treatment can be modified accordingly. Current staging 
protocols define only one axis of tumor progression. Understanding the 
individual phenotype and genotype of a tumor means better treatments and 
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better diagnostics. Until the rules that govern the transformation of tumor 
cells into CSCs are better understood, EMT and the number of cancer stem 
cells should be considered separate metrics. 
Since the pathways for development of cancer stem cells and 
mesenchymal cells are interconnected, a higher ‘score’ for one would 
correlate to a higher ‘score’ for the other. For example, a Stage IIIa cancer 
(or T3N2M0) is more likely to have invasive, motile, poorly differentiated cells 
– but it doesn’t meant it will. Conversely, someone diagnosed with a T2N0M0 
lung adenocarcinoma may see a metastasis a year or more after surgical 
resection. Since most resections have margins free of cancer cells, the most 
likely explanation is that the metastatic cells were already in circulation. An 
‘EMT score’ and ‘CSC index’ may indicate that while the tumor is small, the 
likelihood of recurrence is high; the patient could then receive preventative 
adjuvant therapy and/or radiation (or perhaps a new CSC-specific drug). 
The issue with this model is that EMT itself is non-linear. As 
mentioned in the beginning, the transition from epithelial to mesenchymal 
phenotype is not entirely linear. There are different criteria for what classifies 
“E” versus “M” and some are quantitative (gene expression) and some are 
qualitative (cell morphology). In addition, cancer stem cells are currently 
classified in a binary fashion (tumorigenic or not), but a better understanding 
may alter this definition. Only staging has unambiguous criteria. 
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In summary, a better understanding of tumor composition and better 
quantitation will help us develop more effective treatments which take the 
individual variations of a patient’s disease into account. It will also provide 
better predictions of disease-free survival. 
 
 
Future plans 
 
A test of the hypothesis proposed that EMT facilitates formation of the 
cancer stem cell-containing subpopulation look at in vitro and in vivo 
properties of known cancer cell lines. Spheroid-formation assays and 
implantation of human cancer cell lines into nude rodents would address 
tumorigenicity. This could then be correlated with gene expression of EMT-
correlated genes (i.e. E-cadherin, vimentin, desmoplakin, Twist, Snail, Slug). 
In the future, effective cancer treatment will address epithelial to 
mesenchymal transition and cancer stem cells. Since conventional 
chemotherapy enriches the tumor population for the mesenchymal and stem 
cells (or, at worst, promotes their formation), it may be discarded in favor of 
EMT and CSC targeted therapies. Using small molecules and/or RNAi 
therapy targeted to the EMT/CSC pathways will prevent metastasis and 
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recurrence; without the pool of stem cells, the tumor will theoretically stop 
growing. It may still be necessary to surgically resect the tumor. 
Future tumor treatments should also address the stroma. Since 
cancer-associated fibroblasts provide paracrine signaling and nutrient 
support, attacking the CAFs will deprive the tumor. First, however, we must 
determine what signaling pathways distinguish CAF’s from normal fibroblasts 
to prevent eliminating the latter. 
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Figure 1
Figure 1: The figure illustrates the hallmark properties of a carcinoma. It must evade the normal 
apoptotic mechanisms while dividing indefinitely. It has to produce its own growth signals while 
ignoring signals from the tissue of origin to cease or slow growth. As the tumor grows in size, it 
will release factors promoting angiogenesis, then eventually invade the circulatory or lymph 
system and form a metastatic colony in a new organ.
Figure taken from Hanahan and Weinberg, 2000
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Figure 2
Figure 2: Epithelial to mesenchymal transition involves changes to morphology and gene 
transcription. Figure illustrates the hallmark traits of each state.
Figure taken from Palena et al., 2011
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Figure 3
Figure 3: The left panel shows ovarian cancer cells with the fibroblast-like, spindle morphology 
which is a hallmark of mesenchymal cells. The right panel shows the same cell line after 
treatment with mir-429. It has now reverted to an epithelial phenotype and is rounded in shape.
Figure downloaded from The National Cancer Institute at http://www.cancer.gov/
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Figure 4
Figure 4: The figure illustrates three possible pathways for generation of cancer stem cells. The 
first shows a normal stem cell mutating to become a cancer stem cell. The second pathway 
shows a progenitor cell gaining self-renewal but losing regulated cell division. The last shows a 
terminally differentiated cell gaining self renewal and dedifferentiating to become a stem cell 
once again.
Figure downloaded from the National Institute of Health at http://stemcells.nih.gov
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Figure 5
Figure 5: The figure illustrates the theory that there are multiple tumor cell subpopulations, 
which exist in equilibrium. If separated, the populations will reestablish the original equilibrium 
over time by cells switching from one subtype to another.
Figure taken from Gupta et al., 2011
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Figure 7
Figure 7: TGF-β is secreted once attached to the Latency Associated Protein and the Latent TGF-β-
Binding Protein. Proteolysis releases TGF-β where it binds to TGF-β receptors I and II. The receptors 
phosphorylate each other, as well as their downstream signaling components. Phosphorylation of 
Smad2 and Smad3 activates the final Smad4 complex, which acts as a transcription factor. TGF-βRI 
and TGF-βRII can also activate the MAPK, PI3K, PP2A, Rho, and Par6 pathways.
Figure taken from Li and Flavel, 2008
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Figure 8
Figure 8: TGF-β plays many roles during tumor progression. In the early carcinoma, it inhibits 
growth. As the tumor grows, it promotes EMT and metastasis, while oncogenes suppress the 
inhibitory effects. TGF-β also recruits macrophages, converts effector T cells into regulator T 
cells (less immunogenic). It also contributes to the stromal inflammatory signature, which 
upregulates stromal support of the tumor cells. It promotes osteolysis via IL-11 and parathyroid 
hormone-related protein and angiogenesis via VEGF.
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Figure 9
Figure 9: Reactive oxygen species are mostly generated in the mitochondrium. Leakage of free 
electrons mostly occurs at Complex I. The electron combines with an oxygen molecule to create 
a superoxide radical. Superoxide dismutase 2 converts the superoxide into peroxide, which may 
then be reduced to water.
Figure downloaded from the Mayo Clinic at http://mayoresearch.mayo.edu
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Figure 10
Figure 10: Cellular stress signals upregulate pro-apoptotic proteins like NOXA and PUMA. In the 
absence of Bcl-2 (or other similar proteins) the intrinsic apoptotic pathway is stimulated. Leakage 
of cytochrome C into the cytoplasm recruits Apaf-1 to trigger the caspase cascade. This begins 
apoptosis.
Figure downloaded from Genentech at http://www.biooncology.com/
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Figure 11
Figure 11: Reactive oxygen species are utilized in many EMT-related signaling pathways. This 
includes (but is not limited to) NAPDH, c-Met, Akt, MAPK, and NF-κβ.
Figure taken from Wang et al., 2010
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Figure 12
Figure 12: Twist is upregulated by Hif-1α, which is upregulated in response to hypoxia. Twist 
then upregulates Bmi1, which stimulates genes related both to EMT and stemness.
Figure taken from Martin and Cano, 2010
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Figure 13
Figure 13: Snail is upregulated by both Hif-1α and TGF-β, which are induced by hypoxia. Snail 
upregulates Zeb-1 and Zeb-1, promoting formation of a mesenchymal tumor cell, which 
metastasizes.
Figure taken from Peinado et al., 2007
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Figure 14
Figure 14: Snail is upregulated by multiple pathways, including Atk and NF-κβ. Snail (through 
Zeb-1) downregulates E-cadherin and upregulates N-cadherin, fibronectin, and vimentin. All of 
these effects promote EMT, which in turn promotes invasion, apoptosis resistance, and stem-like 
behavior.
Figure taken from Kumar et al., 2010
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Figure 15
Figure 15: The reverse Warburg effect involves tumor cells creating an inflammatory phenotype 
with ROS in cancer associated fibroblasts. Downregulation of caveolin-1 leads to oxidative 
stress, which reinforces the feedback loop between stress and ROS. This leads to aerobic 
glycolysis and eventually autophagy, both of which provide cancer cells with the high energy 
lactates and ketones, which can then be metabolized in the tumor cells.
Figure taken from Lozy and Karantza, 2012
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Figure 16
Figure 16: After micro RNA is transcribed, it forms a pri-miRNA which is processed by Drosha. It 
then forms a pre-miRNA which is exported into the cytoplasm and is further processed by Dicer. 
The mature miRNA complexes with RISC, at which point it may interact with its target mRNA(s) 
and block translation and/or promote degradation of the target mRNA(s).
Figure downloaded from Immunotrends at http://immunotrends.blogspot.com
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Figure 17
Figure 17: Mir-200 forms a repression loop with Zeb-1. Under epithelial conditions, mir-200 
expression represses Zeb-1 expression, as well as TGF-β expression. However, if Zeb-1 
expression is externally stimulated, it will then repress mir-200 expression. Zeb-1 also repress 
epithelial proteins, the most significant of which is E-cadherin.
Figure taken from McCaffrey and Macara, 2011
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Figure 18
Figure 18: Mir-200 and mir-203 form a repression loop with Zeb-1, Zeb-2, and Snail. The system has two 
states: E-cadherin ‘on’ and ‘off’. In the E-cadherin ‘on’ or “E” state, mir-203, mir-200, and E-cadherin 
expression are high, while the other proteins are low. In the “M” state, the inverse is true. A shows a 
diagram of the miRNA and transcription factor interactions, while B shows the expression levels change 
between the “E” and “M” states.
Figure taken form Moes et al., 2012
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Table 1
Table 1: The table demonstrates the criteria for TNM staging in lung cancer. T is specific to 
tumor size, while N describes the geographic involvement of lymph nodes. A lymph node is 
considered positive if a pathologist finds tumor cells in a lymph node biopsy. M describes 
whether the canecr has metastasized or left the organ. In the case of lung cancer, a primary 
tumor in the left lung (for example) and a lesion in the right lung is considered metastasis.
Table downloaded from The Best Oncologist at http://www.thebestoncologist.com/
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Table 2
Table 2: Many human cancers have a subpopulation that is enriched with cancer stem cells. 
These subpopulations have been identified by their display (or lack of display) of certain cell 
surface markers. The leftmost column specifies the tissue in which the cancer originated and the 
middle column details which cell surface markers are highly expressed in the CSC-enriched 
population. The right column details which cell surface markers are depleted.
Table created using data from citation.
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Table 3
Table 3: The table shows a list of miRNAs whose 
expression is regulated by Zeb-1. The fold change 
is calculated by comparing relative expression with 
and without the presence of constitutively 
expressed Zeb-1. The p value is listed in the 
rightmost column of the table; all p values are < 
0.05.
Table taken from Ahn et al., 2012
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Table 4
Table 4: The table shots a list of clinical trials which use RNAi. The third column indicates the type of 
cancer targeted, while the fourth column indicates the targeted mRNA. One drug may have multiple 
mRNA targets. BCL-2, B-cell CLL/lymphoma 2; LMP2, also known as proteasome subunit beta type 9 
(PSMB9); LMP7, also known as proteasome subunit beta type 8 (PSMB8); MECL1, also known as 
proteasome subunit beta type 10 (PSMB10); Pharm., Pharmaceuticals; PKN3, protein kinase N3; RRM2, 
ribonucleoside-diphosphate reductase subunit M2; VEGF, vascular endothelial growth factor.
Table taken from Davidson and McCray, 2011
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